Brii bags rights to tuberculosis drug to further antibiotic push

Brii Biosciences has licensed the greater China rights to AN2 Therapeutics’ clinical-stage tuberculosis drug. The deal is part of a broader push by Brii to use some of the $260 million it raised last year to bring new antibiotics to patients.